ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $554,117 | -1.7% | 20,417 | +11.3% | 0.03% | +3.3% |
| Q2 2023 | $563,956 | -10.4% | 18,346 | +5.0% | 0.03% | -23.1% |
| Q1 2023 | $629,444 | -24.7% | 17,470 | -17.4% | 0.04% | -27.8% |
| Q4 2022 | $835,453 | +2.3% | 21,140 | +4.0% | 0.05% | -8.5% |
| Q3 2022 | $817,000 | -17.6% | 20,323 | -13.8% | 0.06% | -6.3% |
| Q2 2022 | $992,000 | +3.3% | 23,587 | -4.2% | 0.06% | +57.5% |
| Q1 2022 | $960,000 | -9.1% | 24,630 | -7.1% | 0.04% | +14.3% |
| Q4 2021 | $1,056,000 | +12.1% | 26,499 | +1.6% | 0.04% | +9.4% |
| Q3 2021 | $942,000 | +208.9% | 26,073 | +250.5% | 0.03% | +220.0% |
| Q2 2021 | $305,000 | +4.5% | 7,439 | +11.3% | 0.01% | -9.1% |
| Q1 2021 | $292,000 | -17.5% | 6,685 | -5.4% | 0.01% | -26.7% |
| Q4 2020 | $354,000 | +28.3% | 7,069 | +7.6% | 0.02% | +7.1% |
| Q3 2020 | $276,000 | – | 6,569 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $106,824,000 | 67.12% |
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $269,465,000 | 56.37% |
| Vantage Consulting Group Inc | 4,601,152 | $183,355,000 | 49.30% |
| Indie Asset Partners, LLC | 805,982 | $32,118,000 | 23.31% |
| HARVARD MANAGEMENT CO INC | 3,464,990 | $138,080,000 | 12.96% |
| Brown University | 621,759 | $24,777,000 | 6.04% |
| Overbrook Management Corp | 729,125 | $29,056,000 | 5.86% |
| Bleichroeder LP | 824,033 | $32,838,000 | 5.13% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $7,998,000 | 3.81% |
| Lagoda Investment Management, L.P. | 140,435 | $5,596,000 | 2.65% |